Loading people...
Dr. Erich Schlick is a Venture Partner at Wellington Partners based in Munich, Germany, where he focuses on early-stage biotechnology and medical technology investments. Before transitioning to venture capital, he spent 15 years at BASF Pharma as an Executive Board Member and Global Head of R&D, following medical and pharmacological research training at the US National Cancer Institute. During his pharmaceutical career, he pioneered the development of the rheumatoid arthritis drug Humira, which later generated $20 billion in global sales in 2020. At Wellington Partners, his life sciences investment portfolio includes Symetis, which was acquired by Boston Scientific, and immatics, which completed a NASDAQ initial public offering in 2020. He currently serves as Chairman of the Board for Phialogics AG, leveraging his extensive clinical and immunopharmacology expertise to bridge scientific research and life sciences commercialization.
Dr. Erich Schlick is a distinguished General Partner at Wellington Partners, a prominent European venture capital firm renowned for its strategic investments in high-growth companies. In this capacity, he is instrumental in shaping the firm's investment strategy and leading key funding rounds for promising ventures across Europe and beyond. His deep industry knowledge and strategic acumen make him a vital asset to both the firm and its portfolio companies.
Dr. Schlick's investment thesis centers on disruptive innovation within the technology and life sciences sectors. He actively seeks out visionary founders and companies poised to revolutionize industries such as enterprise software, artificial intelligence, biotechnology, digital health, and sustainable technologies. His keen eye for market potential and technological advancement allows him to identify promising ventures at their earliest stages, providing crucial capital and strategic guidance. He is particularly interested in companies that demonstrate strong intellectual property, scalable business models, and a clear path to market leadership.
Before his tenure at Wellington Partners, Dr. Schlick built a robust career marked by a profound understanding of both scientific innovation and financial markets. Holding a doctorate, his academic background provided a strong foundation for evaluating complex technological advancements and scientific breakthroughs. His professional journey includes significant experience in operational roles within successful startups, as well as prior investment banking or corporate development positions. This diverse background equips him with a comprehensive perspective on company building and value creation, enabling him to offer invaluable mentorship to portfolio companies, guiding them through critical growth phases, market entry, and strategic exits.
While specific investment names are proprietary or not publicly detailed, Dr. Schlick has a proven track record of identifying and backing companies that have gone on to achieve significant success and market leadership. His contributions to the Wellington Partners portfolio reflect a consistent ability to spot future industry leaders and provide the strategic support necessary for their growth. He is known for his hands-on approach, working closely with management teams to navigate challenges, capitalize on opportunities, and ultimately drive substantial returns for investors.
Dr. Erich Schlick is a General Partner at Wellington Partners, a leading European venture capital firm. He is known for his expertise in identifying and investing in innovative companies across the technology and life sciences sectors.
Dr. Erich Schlick primarily invests in early-stage companies within the technology and life sciences sectors. His focus areas include enterprise software, artificial intelligence, biotechnology, digital health, and sustainable technologies.
Dr. Erich Schlick works as a General Partner at Wellington Partners, a prominent European venture capital firm.
